PRESS RELEASE 2015

• Cosmo & Ferring Pharmaceuticals enter into licensing agreement for CORTIMENT®MMX® (budesonide) in Japan

Ferring Pharmaceuticals announced today that it has signed a licensing agreement with Ferring Pharmaceuticals…

• Ferring Pharmaceuticals submits variation application to introduce new tailored dosing regimen in the PICOPREP® (sodium picosulfate, magnesium oxide, citric acid) label

Ferring Pharmaceuticals announced today that it has submitted a variation application in the Mutual Recognition…

• Ferring receives acceptance of Marketing Authorisation filing from EMA for personalised fertility treatment with REKOVELLE® (follitropin delta)

Ferring Pharmaceuticals announced today that the filing for the Marketing Authorisation Application for…

• Ferring Pharmaceuticals acquires global rights to MILPROSA (progesterone vaginal ring)

Ferring Pharmaceuticals announced today that it has acquired the global rights to MILPROSATM (progesterone vaginal ring) from Teva Women’s…

• Ferring Pharmaceuticals begins Phase 2b/3 trial of selepressin for treatment of septic shock

Ferring Pharmaceuticals announced initiation of patient enrollment in a phase 2b/3 clinical trial of selepressin for the treatment of septic shock…

• Ferring Pharmaceuticals moves forward with early stage development of bacteriophage therapy for inflammatory bowel disease

Ferring Pharmaceuticals announced today that it will collaborate with Baltimore-based Intralytix, Inc…

• Inflammatory Bowel Disease Treatment Gets Boost From New Educational Resource

A new educational resource for doctors and healthcare professionals will help improve knowledge and treatment of Inflammatory Bowel Disease (IBD)…

• Ferring and the Institut Pasteur collaborate in novel IBD drug development project

Ferring Pharmaceuticals a research-driven, specialty biopharmaceutical group and the Institut Pasteur, a non-profit international biomedical…

• Ferring announces European approval of new room temperature stable formulation of PABAL® (carbetocin)

Ferring announced today that its new room-temperature-stable formulation of PABAL® (carbetocin) for intravenous (IV) administration…

• Ferring Pharmaceuticals acquires novel drug delivery technology from CTCBIO Inc.

Ferring Pharmaceuticals announced today that it has signed an agreement with CTCBIO Inc. of Seoul, South Korea to acquire rights to…